Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

NCT05618613 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to discontinue onapristone development.

Conditions

Breast Cancer

Interventions

DRUG: Elacestrant
DRUG: Onapristone

Sponsor

Context Therapeutics Inc.